- PR Newswire•24 days agoSun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis
MUMBAI, India and PRINCETON, N.J., Oct. 1, 2016 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries ...
- Reuters•2 months ago
Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States. Net profit for the April-June quarter was 20.34 billion rupees ($304.17 million). Sun had reported a profit of 5.56 billion rupees a year ago, hurt by a big charge related to remediation costs at its drug factories.
- Bloomberg•2 months ago
Sun Pharmaceutical Industries Ltd. reported quarterly profit that more than tripled from a year earlier as its exclusive right to sell the generic version of Novartis AG’s blockbuster cancer drug Gleevec ...
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Delayed Price. Currency in INR
|Day's Range||749.10 - 759.00|
|52wk Range||704.00 - 912.45|
|1y Target Est||N/A|
|P/E Ratio (ttm)||29.30|
|Avg Vol (3m)||2,427,359|
|Dividend & Yield||N/A (N/A)|